skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

T10B9 monoclonal antibody: A short-acting nonstimulating monoclonal antibody that spares γδ T-cells and treats and prevents cellular rejection

Original Research

(2542) Views  (622) Full article downloads

Authors: Thomas H Waid, John S Thompson, Maria Siemionow, Stephen A Brown

Published Date June 2009 Volume 2009:3 Pages 205 - 212
DOI: http://dx.doi.org/10.2147/DDDT.S2750

Thomas H Waid1, John S Thompson1, Maria Siemionow2, Stephen A Brown1

1Department of Internal Medicine, University of Kentucky, Lexington, Kentucky, USA; 2Cleveland Clinic, Cleveland, Ohio, USA

Abstract: T10B9.1A-31/MEDI-500 is a nonmitogenic immunoglobulin M kappa murine monoclonal antibody (mAb) directed against the alpha-beta (αβ) heterodimer of the T-lymphocyte receptor complex. The hybridoma was first produced by fusing spleen cells from BALB/C mice immunized with human peripheral blood T-lymphocytes with SP2/O-Ag14 mutant myeloma cells. The mAb is produced and purified using multistep ion exchange and molecular sieve chromatography protocols. T10B9 has been used successfully to treat acute cellular rejection in renal transplantation and as an immunosuppression induction agent in heart and simultaneous kidney-pancreas transplantation. Because T10B9 is nonmitogenic and causes minimal cytokine release, both treatment of rejection and induction of immunosuppression were accomplished with significantly fewer and milder untoward effects (cytokine release syndrome) than its comparator OKT3. Since T10B9 is directed against the αβ heterodimer of the CD3 epitope, it spares the gamma delta (γδ) region. These gamma delta (γδ) T cells have a unique role in the immune response controlling many serious human diseases and perhaps facilitating the development of immunologic tolerance. T10B9 has a relatively short duration of action, depleting T cells for only 10 to 14 days, unlike the protracted depletion seen with thymoglobulin and Campath-1H. There is no B-lymphocyte depletion with T10B9 as there is with both of the aforementioned reagents. The lack of prolonged lymphocyte depletion may account for less infection observed with T10B9 treatment.

Keywords: T10B9.1A-31, γδ T-cell, monoclonal antibody, Campath-1H, thymoglobulin, OKT3








Readers of this article also read:

Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives
New approaches in the management of multiple sclerosis
Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
Monoclonal antibodies and Fc fragments for treating solid tumors
Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University